Efavirenz News and Research

RSS
Efavirenz, also known as EFV or Sustiva, is a type of medicine called a non-nucleoside reverse transcriptase inhibitor (NNRTI). NNRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself. Efavirenz was approved by the FDA on September 17, 1998, for use with other antiretroviral agents in the treatment of HIV infection in adults and children ages 3 and older. This medicine does not cure HIV infection or AIDS and does not reduce the risk of passing the virus to other people. Efavirenz may also be used with other antiretroviral medications to prevent HIV in people who have been exposed to the virus in the work place, such as health care providers who come in contact with HIV infected blood through an accidental needle stick.
New WHO guidelines recommend earlier treatment for people living with HIV

New WHO guidelines recommend earlier treatment for people living with HIV

FDA approves sNDA for SUSTIVA for treatment of HIV-1 infected pediatric patients

FDA approves sNDA for SUSTIVA for treatment of HIV-1 infected pediatric patients

FDA accepts Merck's NDA for NOXAFIL tablets

FDA accepts Merck's NDA for NOXAFIL tablets

HCV and HIV co-infected patients achieve early treatment success with faldaprevir, PegIFN/RBV

HCV and HIV co-infected patients achieve early treatment success with faldaprevir, PegIFN/RBV

Gilead Sciences fourth quarter total revenues increase 18% to $2.59 billion

Gilead Sciences fourth quarter total revenues increase 18% to $2.59 billion

Janssen announces U.S. prescribing information update for EDURANT tablets

Janssen announces U.S. prescribing information update for EDURANT tablets

IQWiG investigates benefits of rilpivirine for HIV treatment

IQWiG investigates benefits of rilpivirine for HIV treatment

Indonesia issues order to override patents on 7 HIV, hepatitis drugs

Indonesia issues order to override patents on 7 HIV, hepatitis drugs

Efavirenz drug may play a key role in brain damage

Efavirenz drug may play a key role in brain damage

FDA approves Gilead’s Stribild to treat HIV-1 infection

FDA approves Gilead’s Stribild to treat HIV-1 infection

Gilead Sciences receives FDA approval for Stribild to treat HIV-1 infection

Gilead Sciences receives FDA approval for Stribild to treat HIV-1 infection

Gilead Sciences second quarter total revenues increase 13% to $2.41 billion

Gilead Sciences second quarter total revenues increase 13% to $2.41 billion

Merck signs two licensing agreements for investigational HIV drug candidates

Merck signs two licensing agreements for investigational HIV drug candidates

FDA approves 152 antiretroviral drugs in association with PEPFAR to treat HIV/AIDS

FDA approves 152 antiretroviral drugs in association with PEPFAR to treat HIV/AIDS

New FDA guidelines on HIV And TB drug doses may not apply to African and Asian patients

New FDA guidelines on HIV And TB drug doses may not apply to African and Asian patients

All adult patients with HIV should be offered ART: International Antiviral Society-USA panel

All adult patients with HIV should be offered ART: International Antiviral Society-USA panel

Researchers identify high ARV drug exposure in hair samples of HIV uninfected infants

Researchers identify high ARV drug exposure in hair samples of HIV uninfected infants

Gilead receives FDA approval for Truvada to reduce risk of sexually acquired HIV-1 infection

Gilead receives FDA approval for Truvada to reduce risk of sexually acquired HIV-1 infection

Once-daily single-tablet HIV therapy developed

Once-daily single-tablet HIV therapy developed

Dolutegravir-based regimen demonstrates superiority over Atripla in treatment-naive adults with HIV-1

Dolutegravir-based regimen demonstrates superiority over Atripla in treatment-naive adults with HIV-1